CADL Stock Analysis: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$9.83
-0.05 (-0.51%)
▼
5d:
+3.8%
30d:
+16.75%
90d:
+97.39%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 4.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 4.3% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $9.83, which is considered extended relative to its 30-day fair value range of $8.11 to $9.53. From a valuation perspective, the stock is trading at a premium (Forward PE: 44.7) compared to its historical average (39.3). At these levels, the market is pricing in 4.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $7.93, while resistance sits at $11.36.
Market Sentiment: CADL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.29 (+106.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $7.93, while resistance sits at $11.36.
Market Sentiment: CADL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.29 (+106.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.11 -
$9.53
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.4% below Wall St target ($20.29)
- NEUTRAL: Market pricing in 4.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$8.11 -
$9.53
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.93
Resistance Level
$11.36
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
44.68
Wall Street Target
$20.29
(+106.4%)
Valuation Premium vs History
+4.3% premium
PE vs Historical
44.7 vs 39.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.3%
(market-implied from PE analysis)
1-Year Target
$10.25
(+4%)
2-Year Target
$10.69
(+9%)
3-Year Target
$11.15
(+14%)
3-Yr Target (if PE normalizes)
(PE: 45→39)
PE COMPRESSION
$9.81
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 03, 2026 8:55 PM ET
Data refreshes hourly during market hours. Next update: 9:55 PM
Data refreshes hourly during market hours. Next update: 9:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Paul B Manning
BUY
550458 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
